Quantum-Si incorporated Earnings Call Transcripts
Fiscal Year 2025
-
2026 will be a transition year with revenue mainly from consumables, limited new instrument sales, and a focus on preparing for the Proteus launch. Financial discipline is maintained, with strong cash reserves and lower gross margins expected due to revenue mix.
-
Proteus, a next-generation protein sequencing platform, is on track for a 2026 launch, offering major architectural advances for scalability and cost efficiency. Early data show performance exceeding current systems, with commercialization strategies and financial resources in place to support growth.
-
Proteus introduces a scalable, automated protein sequencing platform with a roadmap to detect all 20 amino acids and broad PTM coverage by 2027. The system targets high-value applications, offers lower cost and higher throughput, and is set for commercial launch at the end of 2026, with early access and upgrade programs planned.
-
Q3 2025 revenue was $552,000, with gross margin at 35% and continued capital market headwinds, especially in academia. Strategic placements expanded the install base, and the Proteus platform reached a key prototype milestone. Cash and investments stood at $230.5 million.
-
The event highlighted progress on the Proteus platform, targeting a prototype by year-end and commercial launch next year. Market expansion into biopharma and government sectors, ongoing product and software innovation, and a strong financial position with disciplined spending were emphasized.
-
Panelists highlighted breakthroughs in proteomics and flow cytometry, enabling new research and clinical applications. Strategic adoption, robust pipelines, and AI integration are driving growth despite market challenges, with next-gen platforms and global clinical expansion underway.
-
Next-generation protein sequencing technology is advancing with continuous product improvements, new commercial models, and strong biopharma and defense adoption. The upcoming Proteus platform and AI-driven binder development are set to expand applications and market reach.
-
Q2 2025 revenue fell short due to a near halt in U.S. academic capital sales, but consumable sales exceeded expectations and the pharma/biotech opportunity funnel doubled. New acquisition models and a $50M capital raise aim to drive growth, with a strong cash position extending runway into 2028.
-
Q1 2025 revenue rose 84% year-over-year to $842,000, driven by the Platinum Pro launch, but U.S. academic sales slowed due to NIH funding uncertainty. Focus is shifting to pharma, biotech, and international markets, with strong cash reserves and continued R&D investment supporting long-term growth.
Fiscal Year 2024
-
Q4 2024 revenue grew 52% sequentially and 183% year-over-year, with a diversified customer base and strong international expansion. Cash runway extends into the second half of 2027, with key product launches and the Avantor partnership expected to drive growth in 2025.
-
Proteomics is evolving toward integrated, scalable, and automated platforms, with new products like Platinum Pro and Proteus set to consolidate workflows, expand throughput, and enable advanced applications such as barcoding and ultra-sensitive PTM detection. Strategic partnerships and AI-driven innovation underpin rapid development and market expansion.
-
Q3 2024 revenue fell short of expectations due to delayed customer purchases, but sequential growth is expected in Q4 with confidence in surpassing $1 million in quarterly revenue. Operating expenses rose year-over-year, while cash reserves remain strong, supporting operations into 2026.
-
Platinum’s next-gen protein sequencing technology is gaining traction in academic, pharma, and biotech sectors due to its automation, affordability, and innovative applications. Ongoing product upgrades and customer-driven innovation support expanding use cases, while strong financial discipline and a robust cash position underpin growth plans.
-
A next-generation protein sequencing platform has transitioned from controlled to full commercial launch, rapidly improving chemistry and expanding applications in both academic and pharma/biotech sectors. The company is scaling operations, maintaining strong gross margins, and targeting an $8 billion addressable market with plans for further expansion.
-
Q2 2024 saw the first full quarter of commercial sales, with revenue of $622,000 and a 57% gross margin. Operating expenses and net loss improved year-over-year, and 2024 guidance was reiterated, with cash runway into 2026.